Nuclear imaging modalities for cardiac amyloidosis

Journal of Nuclear Cardiology

Volumn 21, Issue 1, 2014, Pages 175-184

  Bokhari, Sabahat ^a,c   Shahzad, Reehan ^a   Castaño, Adam ^b   Maurer, Mathew S ^b  

^a Nuclear Cardiology Laboratory   (United States)

^b Columbia College of Physicians and Surgeons ^*  (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

Amyloidosis; cardiology; nuclear imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMYLOID; ANTISENSE OLIGONUCLEOTIDE; APROTININ; APROTININ TC 99M; BF 227 C 11; CARBON 11; DIFLUNISAL; DIPHOSPHONO 1,2 PROPANODICARBOXYLIC ACID TC 99M; FLORBETAPIR F 18; GALLIUM 67; INDIUM 111; M11 1F4 I 124; MEDRONATE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; PITTSBURGH COMPOUND B; PREALBUMIN; PYROPHOSPHATE TECHNETIUM TC 99M; SERUM AMYLOID P; SMALL INTERFERING RNA; TAFAMIDIS; TRACER; UNCLASSIFIED DRUG; (3 IODOBENZYL)GUANIDINE; BISPHOSPHONIC ACID DERIVATIVE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 1,1-DIPHOSPHONOPROPANE-2,3-DICARBOXYLIC ACID;

CARDIAC IMAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG BINDING; HEART AMYLOIDOSIS; HEART MUSCLE BIOPSY; HEART SCINTISCANNING; HUMAN; INCIDENCE; ISOTOPE LABELING; NONHUMAN; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC INNERVATION; AMYLOIDOSIS; CARDIOMYOPATHIES; CHEMISTRY; DISEASE COURSE; HEART DISEASE; PROCEDURES; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; AMYLOIDOSIS; CARDIOMYOPATHIES; DIPHOSPHONATES; DISEASE PROGRESSION; HEART DISEASES; HUMANS; IODINE RADIOISOTOPES; ORGANOTECHNETIUM COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; TECHNETIUM; TECHNETIUM TC 99M PYROPHOSPHATE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84893872186     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-013-9803-2     Document Type: Review

References (48)

1. Dharmarajan K, Maurer MS. Transthyretin cardiac amyloidoses in older North Americans. J Am Geriatr Soc 2012;60:765-74.
2. Desai HV, Aronow WS, Peterson SJ, Frishman WH. Cardiac amyloidosis: Approaches to diagnosis and management. Cardiol Rev 2010;18:1-11.
3. Sultan AM, Edwards WD, Mohammed SF, Hammill SC, Bailey KR, Ballard DJ, et al. Cardiac amyloid deposition is common in elderly patients with heart failure and preserved ejection fraction. Circulation 2010;122:A17926.
4. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: A review. J Am Heart Assoc 2012;1:e000364.
5. Falk RH. Cardiac amyloidosis: A treatable disease, often overlooked. Circulation 2011;124:1079-85.
6. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 2007;116:2216-33. (Pubitemid 350060359)
7. Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE, et al. ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;128:e240-327.
8. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013;369:819-29.
9. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 2010;52:347-61.
10. Macario AJ, Conway de Macario E. Sick chaperones and ageing: A perspective. Ageing Res Rev 2002;1:295-311. (Pubitemid 38340347)
11. Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006;13:236-49. (Pubitemid 44764463)
12. Tojo K, Sekijima Y, Kelly JW, Ikeda S. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res 2006;56:441-9. (Pubitemid 44755449)
13. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology 2012;79:785-92.
14. Sah D. Phase I safety, pharmacokinetic and pharmacodynamics results for ALN-TTR01, a novel RNAi therapeutic for the treatment of transthyretin amyloidosis. VIIIth International Symposium on Familial Amyloid Polyneuropathy; 2011.
15. Benson MD, Pandey S, Witchell D, Jazayeri A, Siwkowski A, Monia B, et al. Antisense oligonucleotide therapy for TTR amyloidosis. Amyloid 2011;18:60.
16. Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59. (Pubitemid 24370135)
17. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: Echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997;78:74-82. (Pubitemid 27346885)
18. Gertz MA, Kyle RA, Thibodeau SN. Familial amyloidosis: A study of 52 North American-born patients examined during a 30-year period. Mayo Clin Proc 1992;67:428-40.
19. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: A comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425-9. (Pubitemid 40973426)
20. Kula RW, Engel WK, Line BR. Scanning for soft-tissue amyloid. Lancet 1977;1:92-3.
21. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84. (Pubitemid 41316518)
22. Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011;38:470-8.
23. Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, Ferlini A, et al. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. JACC Cardiovasc Imaging 2012;5:755-8.
24. Kristen AV, Haufe S, Schonland SO, Hegenbart U, Schnabel PA, Röcken C, et al. Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol 2011;43:1862-7.
25. Puille M, Altland K, Linke RP, Steen-Müller MK, Kiett R, Steiner D, et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging 2002;29:376-9. (Pubitemid 34253251)
26. Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659-70.
27. Wizenberg TA, Muz J, Sohn YH, Samlowski W, Weissler AM. Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the non-invasive diagnosis of cardiac amyloidosis. Am Heart J 1982;103:468-73. (Pubitemid 13137994)
28. Gertz MA, Brown ML, Hauser MF, Kyle RA. Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med 1987;147:1039-44. (Pubitemid 17113265)
29. Yamamoto Y, Onoguchi M, Haramoto M, Kodani N, Komatsu A, Kitagaki H, et al. Novel method for quantitative evaluation of cardiac amyloidosis using (201)TlCl and (99m)Tc-PYP SPECT. Ann Nucl Med 2012;26:634-43.
30. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195-201.
31. Camacho V, Carrio I. Targeting neuronal dysfunction and receptor imaging. Curr Opin Biotechnol 2007;18:60-4. (Pubitemid 46227969)
32. Nakata T, Shimamoto K, Yonekura S, Kobayashi N, Sugiyama T, Imai K, et al. Cardiac sympathetic denervation in transthyretin-related familial amyloidotic polyneuropathy: Detection with iodine-12-MIBG. J Nucl Med 1995;36:1040-2.
33. Arbab AS, Koizumi K, Toyama K, Arai T, Yoshitomi T, Araki T. Scan findings of various myocardial SPECT agents in a case of amyloid polyneuropathy with suspected myocardial involvement. Ann Nucl Med 1997;11:139-41. (Pubitemid 27292822)
34. Tanaka M, Hongo M, Kinoshita O, Takabayashi Y, Fujii T, Yazaki Y, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol 1997;29:168-74. (Pubitemid 27028735)
35. Delahaye N, Dinanian S, Slama MS, Mzabi H, Samuel D, Adams D, et al. Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability. Eur J Nucl Med 1999;26:416-24. (Pubitemid 29176454)
36. Hongo M, Urushibata K, Kai R, Takahashi W, Koizumi T, Uchikawa S, et al. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am Heart J 2002;144:122-9. (Pubitemid 34734765)
37. Noordzij W, Glaudemans AW, Rheenen RW, Hazenberg BP, Tio RA, Dierckx RA, et al. (123)I-Labelledmetaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. Eur J Nucl Med Mol Imaging 2012;39:1609-17.
38. Delahaye N, Rouzet F, Sarda L, Tamas C, Dinanian S, Plante-Bordeneuve V, et al. Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. Medicine (Baltimore) 2006;85:229-38. (Pubitemid 44107181)
39. Aprile C, Marinone G, Saponaro R, Bonino C, Merlini G. Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labeled aprotinin. Eur J Nucl Med 1995;22:1393-401. (Pubitemid 26002917)
40. Schaadt BK, Hendel HW, Gimsing P, JÃÂ̧nsson V, Pedersen H, Hesse B, et al. 99mTc-aprotinin scintigraphy in amyloidosis. J Nucl Med 2003;44:177-83.
41. Han S, Chong V, Murray T, McDonagh T, Hunter J, Poon FW, et al. Preliminary experience of 99mTc-aprotinin scintigraphy in amyloidosis. Eur J Haematol 2007;79:494-500. (Pubitemid 350126671)
42. Hawkins PN, Myers MJ, Lavender JP, Pepys MB. Diagnostic radionuclide imaging of amyloid: Biological targeting by circulating human serum amyloid P component. Lancet 1988;1:1413-8.
43. Minamimoto R, Ishii K, Kubota K, Morooka M, Okasaki M, Ito K, et al. Amyloid imaging mismatch. Clin Nucl Med 2012;37:807-9.
44. Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjö L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 2012;54:213-20.
45. Mekinian A, Jaccard A, Soussan M, Launay D, Berthier S, Federici L, et al. 18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: Case-series and literature review. Amyloid 2012;19:94-8.
46. Furukawa K, Ikeda S, Okamura N, Tashiro M, Tomita N, Furumoto S, et al. Cardiac positron-emission tomography images with an amyloid-specific tracer in familial transthyretin-related systemic amyloidosis. Circulation 2012;125:556-7.
47. Wall JS, Kennel SJ, Stuckey AC, et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood 2010;116:2241-4.
48. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F18). J Nucl Med 2010;51:913-20.